alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 551–575 of 619 studies · free to read (page 23 of 25) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 619 studies tagged classification — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Integrative and interpretable framework to unveil the neurophysiological fingerprint of Alzheimer’s disease and mild cognitive impairment: A machine learning-SHAP approach

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Applied Biomedicine 2025-06-13

Dementia and mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) are neurological pathologies associated with disruptions in brain electromagnetic activity, typically studied using magnetoencephalography (MEG) and electroencephalography (EEG). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

An Artificial Intelligence-Driven Multimorbidity Framework Reveals a Shared Metabolic and Immune Core Across Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biomedicines 2026-02-16

Across AD, ALS, and FTD, a convergent multimorbidity architecture centered on a shared metabolic and immune core was identified, accompanied by prominent neurobehavioral processes and intermediate systems including gastrointestinal, endocrine, hematological, hepatic, and sensory pathways. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessing brain vascular impairment, white matter lesions and ApoE status as predictors of behavioral and psychological symptoms of dementia (BPSD) in a multicentre sample of patients with Alzheimer's disease: a multidisciplinary retrospective study

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Annali dell'Istituto superiore di sanita 2025-03-19

BPSD severity was independent from cognitive impairment, vascular impairment, white matter lesions and ApoE status. 3 key findings →

Design: cross-sectional Participants: 92 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multimodal sensing and machine learning for continuous monitoring of agitation in dementia

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer s & Dementia 2025-12-01

So far, we included 42 patients in our study, that were monitored for at least 7 consecutive days and nights, to form the largest database of its kind in the world. 5 key findings →

Participants: 42 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Magnetic Resonance Spectroscopy ( MRS ), Diffusion‐Tensor‐Imaging ( DTI ) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Magnetic Resonance Imaging 2026-03-19

Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017-06-13

In this study, we investigated the effects of chronic administration of an inhibitor of the β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) on Alzheimer-related pathology by multitracer PET imaging in transgenic APPPS1-21 (TG) mice. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain PET in the era of anti-amyloid-β antibody therapy for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Japanese Journal of Radiology 2026-04-25

Here the current and emerging roles of brain positron emission tomography (PET) in Alzheimer's disease (AD) in the era of anti-amyloid-β antibody therapy, with a focus on clinical applications, methodological considerations, and future perspectives were reviewed. 5 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amyloid probability in Alzheimer disease from plasma, cerebrospinal fluid, and amyloid imaging

✓ Peer-reviewed alzhub usefulness score 36 out of 100. npj Dementia 2026-07-01

Blood-based biomarkers are increasingly used to triage patients for amyloid confirmation, yet performance is often reported versus a single comparator despite discordance between amyloid PET and CSF. 1 key finding →

Design: cross-sectional Participants: 320 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine Learning-Based Alzheimer’s Disease Stage Diagnosis Utilizing Blood Gene Expression and Clinical Data: A Comparative Investigation

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Diagnostics 2025-01-17

Utilizing clinical data, the highest ROC AUC scores attained were 0.989, 0.927, and 0.907 for the identification of the CN, MCI, and dementia stages, respectively. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-12-01

The ABC-DS cohort showed similar Aβ PET burden but had a lower prevalence of ApoE4 carriers, younger age at clinical diagnosis and autopsy, shorter PET-autopsy interval, smaller amygdala and hippocampal volumes, more advanced CERAD scores, and no atherosclerosis compared to ADRC cohort (Figure 1). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Detection of Alzheimer and mild cognitive impairment patients by Poincare and Entropy methods based on electroencephalography signals

✓ Peer-reviewed alzhub usefulness score 36 out of 100. BioMedical Engineering OnLine 2025-04-24

Alzheimer's disease (AD) is characterized by deficits in cognition, behavior, and intellectual functioning, and Mild Cognitive Impairment (MCI) refers to individuals whose cognitive impairment deviates from what is expected for their age but does not significantly interfere with daily activities. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Progression-Aware and Explainable CNN–Transformer Framework for Multiclass Alzheimer’s Disease Staging Using MRI

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Diagnostics 2026-02-16

The experimental findings on a multiclass MRI dataset of Alzheimer disease demonstrate consistent and high performance across cross-validation folds (mean F1-score (0.991 ± 0.003) and AUROC (0.9998 ± 0.0002)), without losing transparency and progress awareness. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

‘Machine Learning’ multiclassification for stage diagnosis of Alzheimer’s disease utilizing augmented blood gene expression and feature fusion

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Discover Applied Sciences 2025-06-12

Three blood gene expression datasets of high dimensionality and low sample size (HDLSS) have been utilized in this study, with one dataset exhibiting significant class imbalance. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Graph Spectral Analysis Using Electroencephalography in Alzheimer Disease and Frontotemporal Dementia Patients

✓ Peer-reviewed alzhub usefulness score 35 out of 100. International Journal of Neural Systems 2025-06-12

Graph theory has proven to be useful in studying brain dysfunction in Alzheimer’s disease using MagnetoEncephaloGraphy (MEG) and fMRI signals. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed